Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).

Takahiro NiimuraKoji MiyataHirofumi HamanoYuuki NouninHiroto UntenMasaki YoshinoSatoru MitsuboshiFuka AizawaKenta YagiToshihiro KoyamaMitsuhiro GodaYasunari KandaYuki Izawa-IshizawaYoshito ZamamiKeisuke Ishizawa

Published in: Drug safety (2023)

Systematic evaluation of ALK inhibitor-associated adverse events revealed differences in the cardiotoxicity profiles among ALK inhibitors. Understanding the differences in the cardiovascular toxicity profile of each ALK inhibitor will contribute to safe drug therapy when switching between ALK inhibitors.

Keyphrases

advanced non small cell lung cancer
adverse drug
emergency department
diffuse large b cell lymphoma
drug induced
epidermal growth factor receptor
single cell
stem cells
replacement therapy